HU9602383D0 - Sublingual or buccal pharmaceutical composition - Google Patents
Sublingual or buccal pharmaceutical compositionInfo
- Publication number
- HU9602383D0 HU9602383D0 HU9602383A HU9602383A HU9602383D0 HU 9602383 D0 HU9602383 D0 HU 9602383D0 HU 9602383 A HU9602383 A HU 9602383A HU 9602383 A HU9602383 A HU 9602383A HU 9602383 D0 HU9602383 D0 HU 9602383D0
- Authority
- HU
- Hungary
- Prior art keywords
- sublingual
- pct
- pharmaceutical composition
- buccal
- buccal pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94200521 | 1994-03-02 | ||
PCT/EP1995/000765 WO1995023600A1 (en) | 1994-03-02 | 1995-03-01 | Sublingual or buccal pharmaceutical composition |
Publications (3)
Publication Number | Publication Date |
---|---|
HU9602383D0 true HU9602383D0 (en) | 1996-10-28 |
HUT76319A HUT76319A (en) | 1997-08-28 |
HU225051B1 HU225051B1 (en) | 2006-05-29 |
Family
ID=8216678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9602383A HU225051B1 (en) | 1994-03-02 | 1995-03-01 | Sublingual or buccal pharmaceutical compositions containing trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole |
Country Status (23)
Country | Link |
---|---|
US (1) | US5763476A (hu) |
EP (1) | EP0746317B1 (hu) |
JP (2) | JP4099224B2 (hu) |
KR (1) | KR100330942B1 (hu) |
CN (1) | CN1079670C (hu) |
AT (1) | ATE167057T1 (hu) |
AU (1) | AU692530B2 (hu) |
BR (2) | BR9506924A (hu) |
CA (1) | CA2182981C (hu) |
CZ (1) | CZ284633B6 (hu) |
DE (2) | DE69502939T2 (hu) |
DK (1) | DK0746317T3 (hu) |
ES (1) | ES2118584T3 (hu) |
FI (1) | FI117923B (hu) |
FR (1) | FR10C0056I2 (hu) |
HK (1) | HK1008417A1 (hu) |
HU (1) | HU225051B1 (hu) |
LU (1) | LU91751I2 (hu) |
NO (2) | NO308772B1 (hu) |
NZ (1) | NZ282394A (hu) |
PL (1) | PL180465B1 (hu) |
RU (1) | RU2139051C1 (hu) |
WO (1) | WO1995023600A1 (hu) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2418499A (en) * | 1997-12-19 | 1999-07-12 | Akzo Nobel N.V. | Org-5222 in the treatment of depression |
AU2003211051A1 (en) * | 2002-02-13 | 2003-09-04 | Michael K. Weibel | Drug dose-form and method of manufacture |
US7276246B2 (en) * | 2003-05-09 | 2007-10-02 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
US7306812B2 (en) | 2003-05-09 | 2007-12-11 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
RU2005135454A (ru) * | 2003-05-16 | 2006-06-27 | Пфайзер Продактс Инк. (Us) | Терапевтические комбинации атипичных нейролептиков с модуляторами гамк и/или противосудорожными препаратами |
TWI327915B (en) * | 2003-06-12 | 2010-08-01 | Organon Nv | Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight |
WO2005107808A2 (en) * | 2004-05-11 | 2005-11-17 | Pfizer Products Inc. | Combination of atypical antipsychotics and 5-ht1b receptor antagonists |
GB0416861D0 (en) * | 2004-07-29 | 2004-09-01 | Quadrant Drug Delivery Ltd | Composition |
CA2581188A1 (en) * | 2004-10-15 | 2006-04-20 | Pfizer Inc. | Treatment of bipolar disorders and associated symptoms |
PT1710245E (pt) * | 2005-04-07 | 2007-10-03 | Organon Nv | Forma cristalinade maleato de asenapina |
US7872147B2 (en) | 2005-04-07 | 2011-01-18 | N. V. Organon | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole |
RS51341B (en) | 2005-04-07 | 2011-02-28 | N.V. Organon | INTERMEDIATE COMPOUNDS FOR THE TRANS-5-CHLOR-2-METHYL-2,3A, 12B-TETRAHYDRO-1H-DIBENZE [2,3; 6,7] OXEPINO [4,5-C] Pyrrole |
US7741358B2 (en) * | 2005-04-14 | 2010-06-22 | N.V. Organon | Crystal form of asenapine maleate |
US7750167B2 (en) | 2006-07-05 | 2010-07-06 | N.V. Organon | Process for the preparation of asenapine and intermediate products used in said process |
US7875729B2 (en) | 2007-01-05 | 2011-01-25 | Synthon Bv | Process for making asenapine |
PE20091156A1 (es) * | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
WO2009156889A1 (en) * | 2008-06-25 | 2009-12-30 | Pfizer Inc. | Diaryl compounds and uses thereof |
WO2010127674A1 (en) * | 2009-05-06 | 2010-11-11 | Sunin K/S | Transdermal compositions of asenapine for the treatment of psychiatric disorders |
AU2010264670A1 (en) | 2009-06-24 | 2012-01-19 | Merck Sharp & Dohme B.V. | Injectable formulations containing asenapine and method of treatment using same |
TW201118102A (en) | 2009-07-29 | 2011-06-01 | Organon Nv | Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same |
WO2011159903A2 (en) | 2010-06-18 | 2011-12-22 | Dr. Reddy's Laboratories Ltd. | Asenapine maleate |
ES2466767T3 (es) | 2010-07-29 | 2014-06-11 | Laboratorios Lesvi, S.L. | Nuevo proceso para la preparación de asenapina |
WO2012038975A2 (en) * | 2010-09-22 | 2012-03-29 | Msn Laboratories Limited | Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof |
WO2012068161A1 (en) | 2010-11-15 | 2012-05-24 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
WO2012066565A2 (en) | 2010-11-16 | 2012-05-24 | Cadila Healthcare Limited | Asenapine maleate amorphous and crystalline form and process for preparation thereof |
EP2468750A1 (en) | 2010-12-13 | 2012-06-27 | Chemo Ibérica, S.A. | Polymorphic forms of asenapine maleate and processes for their preparation |
WO2012123325A1 (en) | 2011-03-11 | 2012-09-20 | Medichem S.A. | NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID |
EP2524919A1 (en) | 2011-05-17 | 2012-11-21 | Sandoz AG | Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids |
WO2012156676A1 (en) | 2011-05-18 | 2012-11-22 | Laboratorios Lesvi S.L. | Monoclinic crystalline form of asenapine maleate with a specific particle size distribution |
US9505771B2 (en) * | 2011-05-18 | 2016-11-29 | Laboratories Lesvi S.L. | Stable micronised monoclin form of asenapine maleate and its synthesis |
EP2572703A1 (en) | 2011-09-21 | 2013-03-27 | Hexal AG | Compressed oral dosage form for asenapine maleate |
WO2013041604A1 (en) | 2011-09-21 | 2013-03-28 | Sandoz Ag | Crystal form of asenapine maleate |
CN102657635B (zh) * | 2012-05-04 | 2013-08-07 | 上海现代药物制剂工程研究中心有限公司 | 具有微孔的海绵状的阿塞那平舌下膜剂及其制备方法 |
ITMI20121810A1 (it) | 2012-10-24 | 2014-04-25 | Chemo Iberica Sa | Poliformi di maleato di asenapina e processo per la loro preparazione |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
US9597291B2 (en) | 2012-12-11 | 2017-03-21 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Orally disintegrating tablet containing asenapine |
CN105007899A (zh) | 2012-12-20 | 2015-10-28 | 卡希夫制药有限责任公司 | 用于提高生物利用度的口腔崩解片制剂 |
CN103893139B (zh) * | 2012-12-28 | 2018-06-08 | 石药集团中奇制药技术(石家庄)有限公司 | 一种阿塞那平组合物及其制备方法 |
CN103120688A (zh) * | 2013-01-11 | 2013-05-29 | 盛世泰科生物医药技术(苏州)有限公司 | 一种闪释制剂的药物组合 |
WO2014116770A1 (en) * | 2013-01-23 | 2014-07-31 | Arx, Llc | Production of unit dose constructs |
WO2014127786A1 (en) | 2013-02-22 | 2014-08-28 | Zentiva, K.S. | Orally disintegrating pharmaceutical composition comprising asenapine |
IN2013MU02206A (hu) * | 2013-06-28 | 2015-06-12 | Alembic Pharmaceuticals Ltd | |
EP3083569B1 (en) | 2013-12-20 | 2022-01-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
WO2015125152A2 (en) * | 2014-02-18 | 2015-08-27 | Hetero Research Foundation | Pharmaceutical compositions of asenapine |
US10077267B2 (en) | 2014-04-04 | 2018-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
TR201509009A1 (en) * | 2014-12-11 | 2017-02-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | THIN FILM STRIP OF ASENAPINE |
WO2016198113A1 (en) | 2015-06-11 | 2016-12-15 | Alrise Biosystems Gmbh | Process for the preparation of drug loaded microparticles |
CN108026107B (zh) | 2015-06-19 | 2021-07-30 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
CN113786407A (zh) | 2016-01-26 | 2021-12-14 | 细胞内治疗公司 | 有机化合物 |
KR20230003461A (ko) | 2016-03-25 | 2023-01-05 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
US10085971B2 (en) | 2016-08-22 | 2018-10-02 | Navinta Iii Inc | Pharmaceutical solution of asenapine for sublingual or buccal use |
US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio Inc | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
MX2019007391A (es) | 2016-12-20 | 2019-08-16 | Lts Lohmann Therapie Systeme Ag | Sistema terapeutico transdermico que contiene asenapina. |
CN110087641B (zh) | 2016-12-20 | 2024-03-12 | 罗曼治疗系统股份公司 | 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统 |
US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
JP6987868B2 (ja) | 2016-12-29 | 2022-01-05 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
MX2021013640A (es) | 2017-03-24 | 2022-08-31 | Intra Cellular Therapies Inc | Composiciones novedosas y metodos. |
CN110799180A (zh) | 2017-06-26 | 2020-02-14 | 罗曼治疗系统股份公司 | 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统 |
CA3104478A1 (en) | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
WO2019243452A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
CN112584837A (zh) | 2018-08-31 | 2021-03-30 | 细胞内治疗公司 | 新方法 |
CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7605526A (nl) * | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
IE45770B1 (en) * | 1976-10-06 | 1982-11-17 | Wyeth John & Brother Ltd | Pharmaceutical dosage forms |
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
FR2480283A1 (fr) * | 1980-04-10 | 1981-10-16 | Science Union & Cie | Nouveaux derives tricycliques, leurs procedes de preparation et leur utilisation comme medicament |
JPS5967218A (ja) * | 1982-10-07 | 1984-04-16 | Grelan Pharmaceut Co Ltd | 軟質な口腔製剤 |
GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
CA2027243A1 (en) * | 1989-10-17 | 1991-04-18 | Everett H. Ellinwood, Jr. | Intraoral formulated trifluorobenzodiazepines and the use thereof |
US5496559A (en) * | 1991-04-08 | 1996-03-05 | Sumitomo Pharmaceuticals Company, Limited | Porous solid formulations containing proteinaceous physiologically active substances |
CA2095499A1 (en) * | 1992-05-08 | 1993-11-09 | Petrus J. M. Van Den Oetelaar | Depot preparation |
EP0569096A1 (en) * | 1992-05-08 | 1993-11-10 | Akzo Nobel N.V. | Depot preparation |
-
1995
- 1995-03-01 CZ CZ962541A patent/CZ284633B6/cs not_active IP Right Cessation
- 1995-03-01 ES ES95912188T patent/ES2118584T3/es not_active Expired - Lifetime
- 1995-03-01 KR KR1019960704774A patent/KR100330942B1/ko not_active IP Right Cessation
- 1995-03-01 US US08/693,064 patent/US5763476A/en not_active Expired - Lifetime
- 1995-03-01 EP EP95912188A patent/EP0746317B1/en not_active Expired - Lifetime
- 1995-03-01 AU AU19478/95A patent/AU692530B2/en not_active Expired
- 1995-03-01 AT AT95912188T patent/ATE167057T1/de active
- 1995-03-01 DK DK95912188T patent/DK0746317T3/da active
- 1995-03-01 WO PCT/EP1995/000765 patent/WO1995023600A1/en active IP Right Grant
- 1995-03-01 JP JP52270395A patent/JP4099224B2/ja not_active Expired - Lifetime
- 1995-03-01 PL PL95316080A patent/PL180465B1/pl unknown
- 1995-03-01 CA CA002182981A patent/CA2182981C/en not_active Expired - Lifetime
- 1995-03-01 RU RU96120090/14A patent/RU2139051C1/ru active Protection Beyond IP Right Term
- 1995-03-01 NZ NZ282394A patent/NZ282394A/en not_active IP Right Cessation
- 1995-03-01 DE DE69502939T patent/DE69502939T2/de not_active Expired - Lifetime
- 1995-03-01 BR BR9506924A patent/BR9506924A/pt not_active Application Discontinuation
- 1995-03-01 HU HU9602383A patent/HU225051B1/hu active Protection Beyond IP Right Term
- 1995-03-01 CN CN95191906A patent/CN1079670C/zh not_active Expired - Lifetime
- 1995-03-01 DE DE201012000050 patent/DE122010000050I2/de active Active
-
1996
- 1996-08-30 NO NO19963639A patent/NO308772B1/no not_active IP Right Cessation
- 1996-08-30 FI FI963398A patent/FI117923B/fi not_active IP Right Cessation
-
1997
- 1997-05-13 BR BR1100625-0A patent/BR1100625A/pt active IP Right Grant
-
1998
- 1998-07-14 HK HK98109126A patent/HK1008417A1/xx not_active IP Right Cessation
-
2006
- 2006-08-10 JP JP2006217762A patent/JP4616810B2/ja not_active Expired - Lifetime
-
2010
- 2010-11-04 LU LU91751C patent/LU91751I2/fr unknown
- 2010-12-13 NO NO2010024C patent/NO2010024I2/no unknown
- 2010-12-23 FR FR10C0056C patent/FR10C0056I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU9602383D0 (en) | Sublingual or buccal pharmaceutical composition | |
CA2293823A1 (en) | 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives | |
HUT71814A (en) | Process for producing pharmaceutical compositions for the treatment of neurological lesions related to traumatic injuries | |
UA70298A (uk) | Похідні с-4"-заміщених макролідів, спосіб їх одержання, проміжні сполуки, фармацевтична композиція та спосіб лікування бактеріальної інфекції або протозойної інфекції | |
AU6039194A (en) | Imidazopyridines and their use in treating gastrointestinal diseases | |
IL113566A0 (en) | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration | |
AU2672995A (en) | {a}-annelated pyrrole derivatives and pharmaceutical uses thereof | |
EE03262B1 (et) | Imidaso[1,2-a]püridiinidest saadavad alkoksüalküülkarbamaadid, nende valmistamine ja kasutamine | |
GB9418912D0 (en) | Pharmaceutically active compounds | |
NZ268110A (en) | Use of ropivacaine salt in pharmaceutical compositions for the treatment of pain with sensoric block and minimal motor blockage | |
GR3034142T3 (en) | Composition for the treatment or prevention of herpes | |
HK1011527A1 (en) | Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases | |
IL115004A (en) | Pharmaceutical compositions containing substituted 6-amino-4H-pyrans certain novel such compounds and their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB9A | Succession in title |
Owner name: N.V. ORGANON, NL Free format text: FORMER OWNER(S): AKZO NOBEL N.V., NL; ORGANON (IRELAND) LTD., CH |
|
AA1S | Information on application for a supplementary protection certificate |
Free format text: PRODUCT NAME: AZENAPINE AND IT'S SALT; REG. NO/DATE: EU/1/10/640/001-EU/1/10/640/006 20100901 Spc suppl protection certif: S1000021 Filing date: 20101110 Expiry date: 20150301 |
|
FG4S | Grant of supplementary protection certificate |
Free format text: PRODUCT NAME: ASENAPINE AND IT'S SALT; REG. NO/DATE: EU/1/10/640/001-006 20100901 Spc suppl protection certif: S1000021 Filing date: 20101110 Expiry date: 20150301 Extension date: 20200301 |
|
GB9A | Succession in title |
Owner name: MSD OSS B.V., NL Free format text: FORMER OWNER(S): AKZO NOBEL N.V., NL; N.V. ORGANON,, NL; ORGANON (IRELAND) LTD., CH |
|
GB9A | Succession in title |
Owner name: MERCK SHARP & DOHME B.V., NL Free format text: FORMER OWNER(S): AKZO NOBEL N.V., NL; MSD OSS B.V., NL; N.V. ORGANON,, NL; ORGANON (IRELAND) LTD., CH |